STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2622 by analyst upside · 2026-08-13
HRMY
Harmony Biosciences Holdings, Inc.
Healthcare · Market Cap $2B · P/E 12.9x
ANALYST PRICE TARGET
+15.9%
implied upside to consensus target
Current Price $39.77
Consensus Target $46.1
Bull Target $70.0
Bear Target $30.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
3
Sell
1
52-Week Low $25.52
52-Week High $40.87
YTD Return +6.4%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 12.9x
Forward P/E 5.9x
EPS (TTM) $3.09
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $960M
Profit Margin 18.9%
52-WEEK RANGE
52-Week Low $25.52
52-Week High $40.87
Current Price $39.77
Bear Target $30.0
Bull Target $70.0
● Now $39.77 ● Target $46.1
TRADING DATA
Avg Volume 833K
YTD Return +6.4%
Analyst Count 10
Consensus Buy
Upside to Target +15.9%
Last Updated 2026-08-13

ANALYST SUMMARY

Harmony Biosciences Holdings, Inc. (HRMY) is currently trading at $39.77 with a Wall Street consensus price target of $46.1, implying potential upside of 15.9% over the next 12 months. 10 analysts currently cover HRMY, with a consensus rating of Buy - 60% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $70.0, while the most cautious has a target of $30.0.

HRMY operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 6.4% year-to-date and is currently trading near the upper end of its 52-week range of $25.52 – $40.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for HRMY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities - Reiterated
Hold → Hold 2026-05-08 Building track record
UBS - Reiterated
Neutral → Neutral 2026-02-25 33% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-02-25 31% win rate (48 calls)
B of A Securities - Reiterated
Underperform → Underperform 2026-02-25 Building track record
Needham - Reiterated
Buy → Buy 2026-02-25 20% win rate (5 calls)
UBS ↓ Downgrade
Buy → Neutral 2026-02-11 33% win rate (6 calls)
Truist Securities - Reiterated
Buy → Buy 2026-01-08 Building track record
Mizuho - Reiterated
Outperform → Outperform 2025-12-01 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
18/30
Consensus clarity
10/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →